By Stephen Nakrosis

Pfizer Inc. (PFE) said Thursday the U.S. Food and Drug Administration approved Xeljanz extended-release tablets for adult patients with moderately to severely active ulcerative colitis.

Pfizer said its extended-release 11 mg and 22 mg tablets of Xeljanz, or tofacitinib, was indicated "for the once-daily treatment of adult patients with moderately to severely active ulcerative colitis, after an inadequate response or intolerance to TNF blockers."

Xeljanz is also indicated for the treatment of Rheumatoid Arthritis and Psoriatic Arthritis, the company said.

--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

(END) Dow Jones Newswires

December 12, 2019 18:28 ET (23:28 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Pfizer (NYSE:PFE)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Pfizer Charts.
Pfizer (NYSE:PFE)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Pfizer Charts.